← All trials
NCT05467852
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2022
- Primary completion
- Jan 10, 2025
- Completion date
- Dec 10, 2025
- First posted
- Jul 21, 2022
- Last posted
- Jul 21, 2022
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- First People's Hospital of FoshanCollaborator
- Shenzhen UniversityCollaborator
- Shantou UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.